AKRO — Akero Therapeutics Share News
0.000.00%
Last trade - 00:00Akero shares double after preliminary results from mid-stage trial for liver disease drug
Akero Therapeutics rises after Citi initiates with 'buy' rating
Brief: Akero Therapeutics Reports Q3 2024 Financial Results And Provides Business Update
Akero Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Gold miners , Cytokinetics, Novavax
U.S. STOCKS ON THE MOVE-Chemours, Hyster-Yale, Guidewire
NASH drug developers fall after Eli Lilly's obesity drug shows liver scarring benefit
Brief: Akero Therapeutics Files For Mixed Shelf
Akero Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
Factbox: Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
Brief: Akero Therapeutics Announces Pricing Of Public Offering Of Common Stock
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Brief: Akero Therapeutics Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
Akero Therapeutics up as fatty liver drug reduces scarring in trial
U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
U.S. STOCKS ON THE MOVE-Super Micro Computer, Decker Outdoor, DoorDash
Akero Therapeutics surges as fatty liver drug reduces scarring in trial